Eylea HD 8 MG/0.07 ML vial 0.07ML
Ended Awarded
- Contract number
- SPE2DR26FHCX8
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $10,110
Award facts
- Contract value 100% obligated
- $10,110.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $10,110 to DMS Pharmaceutical Group Inc. for EYLEA HD 8 mg/0.07 ml vials on November 6, 2025, with an ultimate completion date of December 1, 2025. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, was selected without a set-aside designation, demonstrating the company's competitive capability in unrestricted federal procurement. This delivery order was issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $499.999 billion contract awarded on November 13, 2025, that authorizes DLA to issue firm fixed-price orders for comprehensive pharmaceutical products to support Department of Defense healthcare operations globally.
As a critical supplier within the federal pharmaceutical supply chain, DMS Pharmaceutical Group has demonstrated substantial performance across numerous delivery orders for branded and generic prescription medications, biologics, specialty pharmaceuticals, and medical consumables. The PPV-G GEN V contract, structured with a 30-month base period and three 30-month option periods extending through December 31, 2036, positions DMS Pharmaceutical Group as one of multiple regional prime vendor contractors under the broader $30.3 billion PPV-G GEN V acquisition strategy established to meet the recurring medical supply needs of military healthcare facilities worldwide.
Quick answers
Who was awarded contract SPE2DR26FHCX8?
SPE2DR26FHCX8 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on November 6, 2025.
How much is contract SPE2DR26FHCX8 worth?
The government has obligated $10,110 on SPE2DR26FHCX8.
Is contract SPE2DR26FHCX8 an order under another contract?
Yes. SPE2DR26FHCX8 is a delivery order under SPE2DR25D9207, an indefinite delivery contract.
Was contract SPE2DR26FHCX8 competed?
The extent of competition for SPE2DR26FHCX8 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award